Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo

References

• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324
   PubMed Web of Science ®Google Scholar
• Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860
   PubMed Web of Science ®Google Scholar
• Huang M J, Hsieh R K, Lin C P, Chang I Y, Liu H J. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma 2002; 43: 2191–2199
   PubMed Web of Science ®Google Scholar
• Kito M, Matsumoto K, Wada N, Sera K, Futatsugawa S, Naoe T, et al. Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 2003; 94: 1010–1014
   PubMed Web of Science ®Google Scholar
• Rousselot P, Larghero J, Labaume S, Poupon J, Chopin M, Dosquet C, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004; 72: 166–171
   PubMed Web of Science ®Google Scholar
• Lumkul R, Gorin N C, Malehorn M T, Hoehn G T, Zheng R, Baldwin B, et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia 2002; 16: 1818–1826
   PubMed Web of Science ®Google Scholar
• Drize N, Keller J R, Chertkov J L. Local clonal analysis of the hematopoietic system shows that multiple small short-living clones maintain life-long hematopoiesis in reconstituted mice. Blood 1996; 88: 2927–2938
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Guillemin M C, Janin A, Daniel M T, Degos L, Kogan S C, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043–1052
   PubMed Web of Science ®Google Scholar
• Coates A, Tripp E. Comparison of two fluorochromes for flow cytometric assay of cellular glutathione content in human malignant melanoma. Melanoma Res 1995; 5: 107–111
   PubMed Web of Science ®Google Scholar
• Dai J, Weinberg R S, Waxman S, Jing Y. Malignant cells can be sensitized to under growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277
   PubMed Web of Science ®Google Scholar
• Davison K, Cote S, Mader S, Miller W H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003; 17: 931–940
   PubMed Web of Science ®Google Scholar
• Wu X X, Ogawa O, Kakehi Y. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol 2004; 24: 1489–1497
   PubMed Web of Science ®Google Scholar
• Garrido S M, Appelbaum F R, Willman C L, Banker D E. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line, HS-5. Exp Hematol 2001; 29: 448–457
   PubMed Web of Science ®Google Scholar
• Konopleva M, Konoplev S, Hu W, Zaritskey A Y, Afanasiev B V, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713–1724
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158–1165
   PubMed Web of Science ®Google Scholar
• Murdry R E, Fortney J E, York T, Hall B M, Gibson L F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000; 96: 1926–1932
   PubMed Web of Science ®Google Scholar
• Jing Y, Dai J, Chalmers-Redman R ME, Tatton W G, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102–2111
   PubMed Web of Science ®Google Scholar
• Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 2004; 18: 1518–1521
   PubMed Web of Science ®Google Scholar
• Zhou P, Kalakonda N, Comenzo R L. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 2005; 128: 636–644
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hileman E O, Plunkett W, Keating M J, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101: 4098–4104
   PubMed Web of Science ®Google Scholar
• Hazlehurst L A, Landowski T H, Dalton W S. Role of tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003; 22: 7394–7402
   Web of Science ®Google Scholar
• Sethi T, Rintoul R C, Moore S M, MacKinnon A C, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662–668
   PubMed Web of Science ®Google Scholar